Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

John T. Mullen, M.D.

Co-Author

This page shows the publications co-authored by John Mullen and Thomas Delaney.
Connection Strength

3.317
  1. Long-term follow-up of patients treated with neoadjuvant chemotherapy and radiotherapy for large, extremity soft tissue sarcomas. Cancer. 2012 Aug 01; 118(15):3758-65.
    View in: PubMed
    Score: 0.488
  2. Low-dose preoperative radiation, resection, and reduced-field postoperative radiation for soft tissue sarcomas. J Surg Oncol. 2021 Sep; 124(3):400-410.
    View in: PubMed
    Score: 0.233
  3. Preoperative radiotherapy for retroperitoneal sarcoma. Lancet Oncol. 2021 01; 22(1):e1.
    View in: PubMed
    Score: 0.228
  4. What Is the Role of Neoadjuvant Radiation Therapy for Retroperitoneal Sarcoma? Adv Surg. 2020 09; 54:273-284.
    View in: PubMed
    Score: 0.220
  5. Improved local control with an aggressive strategy of preoperative (with or without intraoperative) radiation therapy combined with radical surgical resection for retroperitoneal sarcoma. J Surg Oncol. 2017 May; 115(6):746-751.
    View in: PubMed
    Score: 0.174
  6. Phase 1 trial of preoperative image guided intensity modulated proton radiation therapy with simultaneously integrated boost to the high risk margin for retroperitoneal sarcomas. Adv Radiat Oncol. 2017 Jan-Mar; 2(1):85-93.
    View in: PubMed
    Score: 0.173
  7. Clinical outcomes for patients after surgery and radiation therapy for mesenchymal chondrosarcomas. J Surg Oncol. 2016 Dec; 114(8):982-986.
    View in: PubMed
    Score: 0.171
  8. The Width of the Surgical Margin Does Not Influence Outcomes in Extremity and Truncal Soft Tissue Sarcoma Treated With Radiotherapy. Oncologist. 2016 10; 21(10):1269-1276.
    View in: PubMed
    Score: 0.168
  9. Post-operative renal function following nephrectomy as part of en bloc resection of retroperitoneal sarcoma (RPS). J Surg Oncol. 2015 Jul; 112(1):98-102.
    View in: PubMed
    Score: 0.156
  10. Prognostic significance of treatment-induced pathologic necrosis in extremity and truncal soft tissue sarcoma after neoadjuvant chemoradiotherapy. Cancer. 2014 Dec 01; 120(23):3676-82.
    View in: PubMed
    Score: 0.146
  11. MRI surveillance following treatment of extremity soft tissue sarcoma. J Surg Oncol. 2014 May; 109(6):593-6.
    View in: PubMed
    Score: 0.140
  12. ß-Catenin mutation status and outcomes in sporadic desmoid tumors. Oncologist. 2013; 18(9):1043-9.
    View in: PubMed
    Score: 0.137
  13. Neoadjuvant chemoradiotherapy for patients with high-risk extremity and truncal sarcomas: a 10-year single institution retrospective study. Eur J Cancer. 2013 Mar; 49(4):875-83.
    View in: PubMed
    Score: 0.129
  14. Desmoid tumor: analysis of prognostic factors and outcomes in a surgical series. Ann Surg Oncol. 2012 Dec; 19(13):4028-35.
    View in: PubMed
    Score: 0.128
  15. Prognostic factors and outcomes of patients with myxofibrosarcoma. Ann Surg Oncol. 2013 Jan; 20(1):80-6.
    View in: PubMed
    Score: 0.128
  16. ASO Visual Abstract: Assessing the Safety and Utility of Wound VAC Temporization of the Sarcoma or Benign Aggressive Tumor Bed Until Final Margins are Achieved. Ann Surg Oncol. 2022 04; 29(4):2302-2303.
    View in: PubMed
    Score: 0.062
  17. ASO Visual Abstract: Temporizing Wound VAC Dressing Until Final Negative Margins are Achieved Reduces Myxofibrosarcoma Local Recurrence. Ann Surg Oncol. 2021 12; 28(Suppl 3):475.
    View in: PubMed
    Score: 0.061
  18. Assessing the Safety and Utility of Wound VAC Temporization of the Sarcoma or Benign Aggressive Tumor Bed Until Final Margins Are Achieved. Ann Surg Oncol. 2022 Apr; 29(4):2290-2298.
    View in: PubMed
    Score: 0.061
  19. Temporizing Wound VAC Dressing Until Final Negative Margins are Achieved Reduces Myxofibrosarcoma Local Recurrence. Ann Surg Oncol. 2021 Dec; 28(13):9171-9176.
    View in: PubMed
    Score: 0.059
  20. A Phase 1 Study of Nilotinib Plus Radiation in High-Risk Chordoma. Int J Radiat Oncol Biol Phys. 2018 12 01; 102(5):1496-1504.
    View in: PubMed
    Score: 0.048
  21. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype. J Natl Cancer Inst. 2017 09 01; 109(9).
    View in: PubMed
    Score: 0.045
  22. Preoperative radiation therapy combined with radical surgical resection is associated with a lower rate of local recurrence when treating unifocal, primary retroperitoneal liposarcoma. J Surg Oncol. 2016 Dec; 114(7):814-820.
    View in: PubMed
    Score: 0.042
  23. Acute gastrointestinal toxicity and bowel bag dose-volume parameters for preoperative radiation therapy for retroperitoneal sarcoma. Pract Radiat Oncol. 2016 Sep-Oct; 6(5):360-366.
    View in: PubMed
    Score: 0.040
  24. Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. J Clin Oncol. 2016 Feb 10; 34(5):460-8.
    View in: PubMed
    Score: 0.040
  25. Retroperitoneal sarcoma (RPS) high risk gross tumor volume boost (HR GTV boost) contour delineation agreement among NRG sarcoma radiation and surgical oncologists. Ann Surg Oncol. 2015 Sep; 22(9):2846-52.
    View in: PubMed
    Score: 0.039
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.